SCHEMBL16615959

SCHEMBL16615959

Cc1ncc(CNC(=O)c2cnc(CNS(=O)(=O)c3ccc(Cl)c(F)c3)c(C)n2)s1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 5/20 0.85
GRIN1 Q05586 3/20 0.85
GRIN2B Q13224 2/20 0.85
CXCR4 P61073 1/20 0.40
SCD O00767 1/20 0.37
PIK3CA P42336 5/20 0.36
PIK3CG P48736 5/20 0.36
PIK3CD O00329 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
GRM4 Q14833 2/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
RPS6KA1 Q15418 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16598208 0.93 GRIN2A (0.85) GRIN2AGRIN1GRIN2BCXCR4SCD
SCHEMBL30151536 0.92 GRIN2A (1.00) GRIN2AGRIN1GRIN2BCXCR4SCD
SCHEMBL16615950 0.92 GRIN2A (0.78) GRIN2AGRIN1GRIN2BCXCR4SCD
SCHEMBL16615815 0.92 GRIN2A (1.00) GRIN2AGRIN1GRIN2BCXCR4SCD
SCHEMBL16615960 0.88 GRIN2A (0.82) GRIN2AGRIN1GRIN2BCXCR4SCD
SCHEMBL16598056 0.86 GRIN2A (0.87) GRIN2AGRIN1GRIN2BCXCR4SCD
SCHEMBL16615958 0.86 GRIN2A (0.77) GRIN2AGRIN1GRIN2BPIK3CAPIK3CG
SCHEMBL16615923 0.86 GRIN2A (0.79) GRIN2AGRIN1GRIN2BCXCR4SCD
SCHEMBL16615955 0.86 GRIN2A (0.76) GRIN2AGRIN1GRIN2BCXCR4SCD
SCHEMBL16615921 0.85 GRIN2A (0.75) GRIN2AGRIN1GRIN2BCXCR4SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.